https://www.nature.com/articles/d41586-019-01342-z

But the plan is not without controversy. The RTS,S vaccine only prevents in 4 in 10 malaria cases, and must be given as 4 injections over 18 months. When scientists at the Walter Reed Army Institute of Research in Silver Spring, Maryland, began testing the RTS,S vaccine in 1987, they quickly recognized how hard it would be to target the malaria parasite. Unlike viruses or bacteria, Plasmodium falciparum changes shape in the human body, which makes it hard for attacking proteins triggered by the vaccine to recognize the parasite.

Over the next three decades, GSK and the Bill & Melinda Gates Foundation in Seattle, Washington, supported development of the vaccine — at a cost of $700 million. The effort culminated in 2015, when a 15,000-person clinical trial found that giving four doses of RTS,S over 18 months cut the number of malaria episodes that young children experienced by 36%¹.But data from an earlier trial suggest that that the partial protection fades over several years². And a deep dive into data from the 2015 trial revealed that girls who had received the RTS,S vaccine were slightly more likely than those who weren’t vaccinated to die from all causes — including severe malaria³.

Доказательная медицина, COVID-19, ЗОЖ